Evaluating clinical response to primary endocrine therapy in elderly breast cancer patients in routine practice.

IF 3 3区医学 Q2 ONCOLOGY

Breast Cancer Research and Treatment Pub Date : 2025-11-01 Epub Date: 2025-09-12 DOI:10.1007/s10549-025-07809-0

Tessa L Dinger, José H Volders, Anne Kuijer, Johannes C Kelder, Annemiek Doeksen, Emily L Postma, Thijs van Dalen

{"title":"Evaluating clinical response to primary endocrine therapy in elderly breast cancer patients in routine practice.","authors":"Tessa L Dinger, José H Volders, Anne Kuijer, Johannes C Kelder, Annemiek Doeksen, Emily L Postma, Thijs van Dalen","doi":"10.1007/s10549-025-07809-0","DOIUrl":null,"url":null,"abstract":"Purpose: Endocrine therapy (ET) can be used as a definitive treatment in frail and elderly breast cancer patients who are unwilling or deemed unfit to undergo surgical treatment. This study evaluated the clinical response to ET as primary treatment in elderly patients with non-metastatic, oestrogen receptor (ER) positive breast cancer, by evaluating its effectiveness over time.Methods: Elderly patients (≥ 70 years) with ER-positive breast cancer who had been treated with ET as primary treatment between 2008 and 2015 in two Dutch hospitals were identified through the Netherlands Cancer Registry. The primary outcome was the objectively measured clinical response at various time intervals after initiation of ET.Results: Out of 122 patients (median age, 86 years), 100 (82%) received ET as definitive treatment, whereas 22 (18%) received ET as neo-adjuvant endocrine therapy. Over the 3-year observation period, 25% of patients had died and 29% underwent invasive local treatment. The overall response rate after 3 years was 14% for all 122 patients and 30% for the 56 patients who were still alive and had not undergone local treatment after 3 years.Conclusion: The observed clinical response to ET in a consistent proportion of patients over time suggests it may be a viable option for a selection of frail and elderly breast cancer patients with limited life expectancy.","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"215-222"},"PeriodicalIF":3.0000,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12464097/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10549-025-07809-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/12 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Endocrine therapy (ET) can be used as a definitive treatment in frail and elderly breast cancer patients who are unwilling or deemed unfit to undergo surgical treatment. This study evaluated the clinical response to ET as primary treatment in elderly patients with non-metastatic, oestrogen receptor (ER) positive breast cancer, by evaluating its effectiveness over time.

Methods: Elderly patients (≥ 70 years) with ER-positive breast cancer who had been treated with ET as primary treatment between 2008 and 2015 in two Dutch hospitals were identified through the Netherlands Cancer Registry. The primary outcome was the objectively measured clinical response at various time intervals after initiation of ET.

Results: Out of 122 patients (median age, 86 years), 100 (82%) received ET as definitive treatment, whereas 22 (18%) received ET as neo-adjuvant endocrine therapy. Over the 3-year observation period, 25% of patients had died and 29% underwent invasive local treatment. The overall response rate after 3 years was 14% for all 122 patients and 30% for the 56 patients who were still alive and had not undergone local treatment after 3 years.

Conclusion: The observed clinical response to ET in a consistent proportion of patients over time suggests it may be a viable option for a selection of frail and elderly breast cancer patients with limited life expectancy.

查看原文本刊更多论文

评价老年乳腺癌患者原发性内分泌治疗的临床疗效。

目的：内分泌治疗（ET）可作为虚弱和老年乳腺癌患者不愿或认为不适合接受手术治疗的决定性治疗方法。本研究评估了ET作为老年非转移性雌激素受体（ER）阳性乳腺癌患者的主要治疗的临床反应，通过评估其随时间的有效性。方法：通过荷兰癌症登记处确定2008年至2015年期间在两家荷兰医院接受ET作为主要治疗的er阳性乳腺癌老年患者（≥70岁）。结果：122例患者（中位年龄86岁）中，100例（82%）接受ET作为最终治疗，而22例（18%）接受ET作为新辅助内分泌治疗。在3年的观察期内，25%的患者死亡，29%的患者接受了有创的局部治疗。122例患者3年后的总有效率为14%，56例患者3年后仍存活且未接受局部治疗的总有效率为30%。结论：随着时间的推移，观察到的ET在一致比例的患者中的临床反应表明，对于预期寿命有限的体弱和老年乳腺癌患者来说，它可能是一种可行的选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast Cancer Research and Treatment 医学-肿瘤学

CiteScore

6.80

自引率

2.60%

发文量

342

审稿时长

1 months

期刊介绍： Breast Cancer Research and Treatment provides the surgeon, radiotherapist, medical oncologist, endocrinologist, epidemiologist, immunologist or cell biologist investigating problems in breast cancer a single forum for communication. The journal creates a "market place" for breast cancer topics which cuts across all the usual lines of disciplines, providing a site for presenting pertinent investigations, and for discussing critical questions relevant to the entire field. It seeks to develop a new focus and new perspectives for all those concerned with breast cancer.